Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Retigabine: Completed Phase III enrollment

VRX completed enrollment of 539 patients in the double-blind, placebo-controlled, international Phase III RESTORE2

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE